UFLEX

H1 FY26 showcased robust volume growth and impressive PAT expansion, the revised full-year guidance reflects significant import pressures. The success of strategic capacity expansions by FY27 will be critical in mitigating these headwinds and driving the projected revenue recovery. Management's disciplined capital structure and cost focus are commendable amidst these ***** firm's H1 FY26 performance was marked by a striking 150% surge in PAT, largely normalizing from prior period currency impacts, complemented by a robust 5.5% increase in packaging unit volumes despite a more modest 3% sales uptick. Strategic capacity expansions, including an aseptic line extension and a new BOPP facility, alongside global projects in PET recycling, aseptic packaging, and WPP, are slated to boost future capabilities by Q1 FY27. Near-term, however, significant headwinds from soaring PET and BOPP imports have tightened margins and prompted a recalibrated FY26 revenue growth forecast of 5%. Management eyes a return to 10% revenue growth in FY27, contingent on timely project commissioning. With net debt at ₹7,750 crore, the focus remains on achieving a 2.8–3x debt/EBITDA by FY27 through operational efficiencies and targeted investments, without immediate equity dilution. Despite significant near-term import pressures, the company's aggressive capacity expansions and disciplined financial strategy position it well for long-term growth. Successful project commissioning is paramount for FY27's projected revenue acceleration and market positioning. Close monitoring of execution, especially amidst global trade dynamics, remains critical.